BACKGROUND: Early studies of high-dose chemotherapy (HDC) for breast cancer were limited by small numbers and the lack of adequate control groups. The French PEGASE Group was founded to perform larger and properly randomized comparative studies of this approach. METHODS: The program was created to determine the effects of intensive chemotherapy for breast cancer. The seven PEGASE protocols addressed HDC as adjuvant therapy (01 and 06) and as treatment for inflammatory nonmetastatic disease (02, 05, and 07) and metastatic disease (03 and 04). Two of these protocols are ongoing. RESULTS: The PEGASE 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the HDC arm but overall survival was unchanged. The ongoing phase III 06 trial is studying a higher dosage regimen. The HDC trials for metastatic and inflammatory nonmetastatic disease are encouraging. CONCLUSIONS: Many clinicians no longer subscribe to the concept of HDC for breast cancer. Overall outcomes from management of poor-risk breast cancer remain poor, however, and it is possible that some selected subgroups of patients may benefit from such an approach.
BACKGROUND: Early studies of high-dose chemotherapy (HDC) for breast cancer were limited by small numbers and the lack of adequate control groups. The French PEGASE Group was founded to perform larger and properly randomized comparative studies of this approach. METHODS: The program was created to determine the effects of intensive chemotherapy for breast cancer. The seven PEGASE protocols addressed HDC as adjuvant therapy (01 and 06) and as treatment for inflammatory nonmetastatic disease (02, 05, and 07) and metastatic disease (03 and 04). Two of these protocols are ongoing. RESULTS: The PEGASE 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the HDC arm but overall survival was unchanged. The ongoing phase III 06 trial is studying a higher dosage regimen. The HDC trials for metastatic and inflammatory nonmetastatic disease are encouraging. CONCLUSIONS: Many clinicians no longer subscribe to the concept of HDC for breast cancer. Overall outcomes from management of poor-risk breast cancer remain poor, however, and it is possible that some selected subgroups of patients may benefit from such an approach.
Authors: Yee Chung Cheng; Gabriela Rondón; Leah F Sanchez; John D McMannis; Daniel R Couriel; Marcos J de Lima; Chitra Hosing; Issa F Khouri; Sergio A Giralt; Richard E Champlin; Naoto T Ueno Journal: Int J Hematol Date: 2009-12-09 Impact factor: 2.490
Authors: Donald A Berry; Naoto T Ueno; Marcella M Johnson; Xiudong Lei; Jean Caputo; Dori A Smith; Linda J Yancey; Michael Crump; Edward A Stadtmauer; Pierre Biron; John P Crown; Peter Schmid; Jean-Pierre Lotz; Giovanni Rosti; Marco Bregni; Taner Demirer Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Donald A Berry; Naoto T Ueno; Marcella M Johnson; Xiudong Lei; Jean Caputo; Sjoerd Rodenhuis; William P Peters; Robert C Leonard; William E Barlow; Martin S Tallman; Jonas Bergh; Ulrike A Nitz; Alessandro M Gianni; Russell L Basser; Axel R Zander; R Charles Coombes; Henri Roché; Yutaka Tokuda; Elisabeth G E de Vries; Gabriel N Hortobagyi; John P Crown; Paolo Pedrazzoli; Marco Bregni; Taner Demirer Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Tessa G Steenbruggen; Lars C Steggink; Caroline M Seynaeve; Jacobus J M van der Hoeven; Maartje J Hooning; Agnes Jager; Inge R Konings; Judith R Kroep; Wim M Smit; Vivianne C G Tjan-Heijnen; Elsken van der Wall; Adriaan D Bins; Sabine C Linn; Michael Schaapveld; Judy N Jacobse; Flora E van Leeuwen; Carolien P Schröder; Harm van Tinteren; Elisabeth G E de Vries; Gabe S Sonke; Jourik A Gietema Journal: JAMA Oncol Date: 2020-04-01 Impact factor: 31.777
Authors: Claude Sportès; Seth M Steinberg; David J Liewehr; Juan Gea-Banacloche; David N Danforth; Daniele N Avila; Kelly E Bryant; Michael C Krumlauf; Daniel H Fowler; Steven Pavletic; Nancy M Hardy; Michael R Bishop; Ronald E Gress Journal: Biol Blood Marrow Transplant Date: 2009-08 Impact factor: 5.742
Authors: Lawrence B Marks; Constance Cirrincione; Thomas J Fitzgerald; Frances Laurie; Arvin S Glicksman; James Vredenburgh; Leonard R Prosnitz; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Jinli Ma; Bercedis L Peterson; Larry Norton; Steven Seagren; I Craig Henderson; David D Hurd; William P Peters Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-09 Impact factor: 7.038
Authors: L Boudin; A Gonçalves; R Sabatier; J Moretta; P Sfumato; P Asseeva; D Livon; F Bertucci; J-M Extra; C Tarpin; G Houvenaeghel; E Lambaudie; A Tallet; M Resbeut; H Sobol; E Charafe-Jauffret; B Calmels; C Lemarie; J-M Boher; P Viens; F Eisinger; C Chabannon Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483